A Study of LY900014 (Lyumjev) Versus Insulin Lispro (Humalog) in Participants With Type 1 Diabetes
Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
This study will be conducted in participants with type 1 diabetes mellitus on continuous
subcutaneous insulin infusion (CSII) or pump therapy to evaluate the effect of LY900014
(Lyumjev) on blood sugar levels during exercise using different approaches on basal rate
reduction and following a test meal compared to insulin lispro (Humalog). The study may last
up to approximately 10 weeks and may include up to 7 visits.